LD-2 disclosure · 3rd Quarter - Report
CARA THERAPEUTICS
Coverage · No income or expenses were reported on this filing.
Client
- Description
- biotechnology company
- Location
- Connecticut · United States of America
Registrant
- Description
- law firm
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
1 issueMedicare/Medicaid
ESRD prospective payment system CY 2022 proposed rule and guidance; Medicare Advantage Program; S. 1971/H.R. 4065 "Chronic Kidney Disease Improvement in Research and Treatment Act of 2021."
LobbyistsKATHLEEN LESTER
TargetedSENATE · HOUSE OF REPRESENTATIVES · Centers For Medicare and Medicaid Services (CMS)